Lipoxen raises £2.6 million through Strategic Placing and Warrant Agreement with Serum Institute of India Limited

07-Aug-2006

Lipoxen PLC has raised £2.6 million in new funds from the Serum Institute of India Limited ("SIIL") through a subscription agreement and associated warrant agreement. Pursuant to the subscription agreement, the Company has agreed to issue to SIIL 10,000,000 ordinary shares in the Company at a subscription price of 26 pence per share ("Subscription Shares"). The completion of the subscription is conditional upon, inter alia, the admission of the Subscription Shares to trading on AIM. The Subscription Shares, once issued, will rank pari passu in all respects with the existing issued ordinary share capital of the Company. Application will be made to the London Stock Exchange plc for these shares to be admitted to trading on AIM.

SIIL is a beneficial holder of 4.10% in the current issued share capital of the Company. Following the issue of the Subscription Shares, SIIL will hold approximately 12% of the enlarged issued share capital in the Company. The Company has also entered into a warrant agreement with SIIL pursuant to which the Company has granted SIIL the right to subscribe for up to 2.7 million ordinary shares in the Company for a period of two years from 3 August 2006 at a subscription price of 35 pence per share.

Following the issue of the Subscription Shares to SIIL and assuming the exercise of SIIL's rights under the warrant agreement, SIIL will hold approximately 14% of the enlarged issued share capital of the Company.

As part of these agreements, SIIL has also been granted the right to appoint a non-executive director to the board of the Company. This right may only be exercised in the event SIIL holds no less than 12% of the total issued share capital of the Company. The funds raised through the subscription will allow the Company to drive clinical development of its pipeline of potential protein drugs and vaccines into clinical trials and appoint a leading biologic Contract Research Organisation. It will also allow Lipoxen to recruit additional laboratory staff in order to capitalize on the potential to broaden the Company's revenue generating collaborations.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances